Navigation Links
Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA
Date:10/5/2007

m (n=3,920), cases of

rash, some of which were severe, accompanied by myalgia, fever,

erythema, desquamation, and mucosal erosions were reported.

Discontinue and initiate appropriate treatment if severe skin rash

develops.

-- APTIVUS should be used with caution in patients with a known

sulfonamide allergy.

-- New onset diabetes mellitus, exacerbation of pre-existing diabetes

mellitus, hyperglycemia and increased bleeding (in patients with

hemophilia) have been reported in patients taking protease inhibitors.

A causal relationship between protease inhibitors and these events has

not been established.

-- Immune reconstitution syndrome has been reported in patients treated

with combination antiretroviral therapy, including APTIVUS/r.

-- Redistribution and/or accumulation of body fat have been observed in

patients receiving antiretroviral therapy. A causal relationship has

not been established.

-- Treatment with APTIVUS/r has resulted in large increases in total

cholesterol and triglycerides, which should be monitored prior to and

during APTIVUS/r therapy.

-- Because the potential for HIV cross-resistance among protease

inhibitors has not been fully explored in APTIVUS/r-treated patients,

it is unknown what effect therapy with APTIVUS will have on the

activity of subsequently administered protease inhibitors.

-- APTIVUS must be co-administered with 200 mg of ritonavir to exert its

therapeutic effect. Failure to correctly co-administer APTIVUS with

ritonavir will result in reduced plasma levels of tipranavir that will

be insufficient to achieve the desired antiviral effect and will alter

some drug interactions.

-- Please refer to the complete ritonavir prescribing information for a

description of ritonavir contraindications and
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Allos Therapeutics PDX Granted Orphan Medicinal Product Designation by the European Commission
2. Pixantrone Granted Fast Track Designation by FDA for Relapsed Indolent NHL Patients
3. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Va. , Aug. 27, 2015  The ... the Food and Drug Administration,s (FDA,s) draft guidance ... reference products and biosimilars, to bear a nonproprietary ... AMCP has been seeking a decision from the ... 18 diverse health care stakeholders urging the agency ...
(Date:8/27/2015)... Biosimilars are not generics and the ... and Drug Administration (FDA) for recognizing that each ... guidance issued today. The FDA,s draft guidance on ... calling for biological products to bear a nonproprietary ... reflects the agency,s thinking that "there is a ...
(Date:8/27/2015)... INDIANAPOLIS , Aug. 27, 2015  Eli Lilly ... Morgan Stanley Global Healthcare Conference on Thursday, September 17, ... and president of Lilly Oncology and Richard Gaynor ... medical affairs for Lilly Oncology, will participate in a ... A live audio webcast will be available ...
Breaking Medicine Technology:AMCP Is Disappointed in FDA's Draft Guidance and Proposed Rule Calling for Suffix on Nonproprietary Names of Biological Products 2Biologics Prescribers Collaborative (BPC) Statement on FDA Draft Guidance entitled "Nonproprietary Naming of Biological Products" 2Lilly to Participate in Morgan Stanley Global Healthcare Conference 2
... , VIENNA, Va., Jan. 11 CEL-SCI Corporation ... a developer of vaccines and therapeutics for the prevention and ... validation of all critical utilities and manufacturing equipment at its ... represents a very important milestone as it allows CEL-SCI to ...
... SANTA MONICA, Calif., Jan. 11 Derycz Scientific (OTC Bulletin Board: ... the flow of information from content publishers to enterprise customers and ... 2010, on the website of DDN ( Drug Discovery ... Peter Derycz, is titled "Speeding the Path to FDA Approval in ...
Cached Medicine Technology:CEL-SCI Completes Validation of Manufacturing Facility Allowing It To Commence Manufacturing of Multikine 2CEL-SCI Completes Validation of Manufacturing Facility Allowing It To Commence Manufacturing of Multikine 3CEL-SCI Completes Validation of Manufacturing Facility Allowing It To Commence Manufacturing of Multikine 4Derycz Scientific Featured In DDN (Drug Discovery News) 2Derycz Scientific Featured In DDN (Drug Discovery News) 3
(Date:8/28/2015)... ... August 28, 2015 , ... The Kentucky State Department of Workforce Investment Commissioner ... they are applying for, they are unable to pass the initial drug test and ... testing policies in order to be able to hire long-term, skilled talent. (1) Will ...
(Date:8/28/2015)... Dallas, TX (PRWEB) , ... August 28, 2015 , ... ... Surgical Center is taking part with their subsidiary USPI Tenet Health. , The American ... to fight heart disease and stroke. They believe that together, a difference can be ...
(Date:8/28/2015)... ... , ... The 6th Annual Survivor in the City, Chicago silent auction ... accolade to its cadre of widespread support—an official letter of support and gratitude from ... medical community and the University of Illinois at Chicago’s Department of Neurosurgery, the Brain ...
(Date:8/28/2015)... ... August 28, 2015 , ... Saint Petersburg, FL ... with zero fat, carbs, sugar, gluten, lactose or caffeine in a convenient 2 ... 2015 SupplySide CPG Editor’s Choice Awards. , Five consumer packaged goods (CPG) products ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... nationwide. Addictions specialist, Dr. James Strawbridge, gives a new approach on solutions in ... should begin with the employer and employees getting together for meaningful group meetings. ...
Breaking Medicine News(10 mins):Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3
... Ended 2007, BANGOR, Maine, Oct. 15 Nyer Medical ... results for its,fiscal year ended June 30, 2007. Revenues increased ... compared to $63,596,975 as reported for,the same period ended June ... $.02 basic net earnings per common share for the year ...
... centers did as well, 266,604 fewer patients would die ... -- Patients in the top-ranked hospitals in the United ... those in the lowest-rated hospitals, according to a new ... 10th annual HealthGrades Hospital Quality in America Study looked ...
... mechanisms involved in resistance to treatment of breast cancer ... Press in the October issue of the journal ... identify patients who are unlikely to respond to trastuzumab ... patients. , Trastuzumab is an antibody used as a ...
... FORT WORTH, Texas, Oct. 15 DSS Research asked ... around PFFS sales,practices in their June Senior Trax(TM) survey. ... Medicare eligibles. Overall, 13.3% said they,had heard or read ... past two months. This figure ranged from a high ...
... Nine of Texas, 181,legislators are being honored ... of their accomplishments on behalf of health care,during ... Texas Hospital,Association created the award in 1997 to ... outstanding leadership on issues important,to hospitals and health ...
... NEW YORK, Oct. 15 L,Oreal Paris, the worldwide ... Mexoryl SX (ecamsule), a new daily moisturizer with advanced ... rays -- the number,one cause of skin aging. After ... exclusive to L,Oreal, has been,approved in a formula by ...
Cached Medicine News:Health News:Nyer Medical Group, Inc. Reports EPS of $.02 on Record Revenues of $69.9 Million for Fiscal Year Ended 2007 2Health News:Nyer Medical Group, Inc. Reports EPS of $.02 on Record Revenues of $69.9 Million for Fiscal Year Ended 2007 3Health News:Nyer Medical Group, Inc. Reports EPS of $.02 on Record Revenues of $69.9 Million for Fiscal Year Ended 2007 4Health News:America's Top Hospitals Are Real Lifesavers 2Health News:Genetic approach provides new insight into trastuzumab resistance in breast cancer 2Health News:THA Honors Nine Legislators for Contributions to Health Care 2Health News:Video: New FDA-Approved Sun Protectant Saves Skin All Year Round 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: